Clin J Sport Med. 2002 Nov;12(6):387-90.
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
Chu KS, Doherty TJ, Parise G, Milheiro JS, Tarnopolsky MA.
Department of Medicine (Rehabilitation and Neurology), McMaster University, Hamilton, Ontario, Canada.
OBJECTIVE: To investigate the effect of an acute oral administration of pseudoephedrine (PSE) on muscle function, fatigue, and anaerobic power output. DESIGN AND MATERIALS: Healthy males (N = 10) and females (N = 10) were allocated to receive both a placebo and PSE (120 mg) using a randomized, double-blind, crossover experimental design. Each subject had their maximal voluntary contraction strength and fatigability measured for both handgrip and ankle dorsi-flexion. Following the strength measurements, a 30-second maximal cycle test was performed to determine lower extremity anaerobic power and fatigue. Plasma lactate was measured before and after exercise. RESULTS: There were no significant differences in any of the outcome variables between the placebo and PSE trials. CONCLUSIONS: These results demonstrated that a 120 mg dose of PSE did not enhance force production, time to fatigue, fatigue index, or power output in young men or women. Therefore, there does not appear to be an ergogenic benefit from the ingestion of 120 mg PSE in high-intensity exercise performance.
Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 12466695 [PubMed - indexed for MEDLINE]
Br J Clin Pharmacol. 2000 Sep;50(3):205-13.
Muscular and cardiorespiratory effects of pseudoephedrine in human athletes.
Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP.
Centre for Sport and Exercise Science, The Waikato Polytechnic, Private Bag HN 3036, Hamilton, New Zealand.
AIMS: Pseudoephedrine (PSE) is a readily available over-the-counter nasal decongestant which is structurally similar to amphetamine and is included on the International Olympic Committee's list of banned substances. However to date, little research has supported its putative ergogenic effect. This study investigated whether a 180 mg dose of PSE ingested 45 min prior to exercise enhanced short-term maximal exercise performance and/or altered related physiological variables. METHODS: A randomised, double-blind, crossover study in 22 healthy male athletes. RESULTS: Maximum torque (mean +/- s.d., n = 22) produced in an isometric knee extension exercise was 321.1+/-62.0 Nm (PSE) and 295.7+/-72.4 Nm (placebo), and peak power obtained on the 'all-out' 30 s cycle test was 1262.5+/-48.5 W (PSE) and 1228.4+/-47.1 W (placebo) (P<0.01, P<0.03, respectively). Subjects were estimated to be producing 96.9+/-2.4% of their maximal possible isometric leg extension force after PSE ingestion, but only 95.3+/-2.4% when PSE was not ingested. Bench press tasks and total work during the cycle test were not affected by the ingestion of PSE. Lung function was altered following ingestion of PSE (P<0.05) with FEV1 and FVC significantly increased (P<0.02, P<0.01, respectively) although the FEV1/FVC ratio was not altered. Heart rate was significantly elevated by the ingestion of PSE immediately following the 30 s cycle sprint (P<0.01) however, lactate concentration was not altered by the ingestion of PSE. CONCLUSIONS: The administration of a 180 mg dose of PSE increased maximum torque, produced in an isometric knee extension and produced an improvement in peak power during maximal cycle performance, as well as improving lung function.
Publication Types:
Clinical Trial
Randomized Controlled Trial